NCT02015169View on ClinicalTrials.gov

Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 9, 2012

Primary Completion Date

July 17, 2017

Study Completion Date

November 17, 2017

Conditions
HER2-positive Gastric Cancer Patients With Liver Metastasis
Interventions
DRUG

Lapatinib

lapatinib 1250mg qd daily up to 8 cycles (3 weeks \* 8 cycles = 24 weeks)

Trial Locations (1)

135-720

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02015169 - Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis | Biotech Hunter | Biotech Hunter